BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koh C, Heller T, Glenn JS. Pathogenesis of and New Therapies for Hepatitis D. Gastroenterology. 2019;156:461-476.e1. [PMID: 30342879 DOI: 10.1053/j.gastro.2018.09.058] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Masetti C, Aghemo A. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int 2021;41:1441-2. [PMID: 34139064 DOI: 10.1111/liv.14967] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jung S, Altstetter SM, Protzer U. Innate immune recognition and modulation in hepatitis D virus infection. World J Gastroenterol 2020; 26(21): 2781-2791 [PMID: 32550754 DOI: 10.3748/wjg.v26.i21.2781] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Usai C, Maestro S, Camps G, Olague C, Suárez-Amaran L, Vales A, Aragon T, Hommel M, Aldabe R, Gonzalez-Aseguinolaza G. TNF-alpha inhibition ameliorates HDV-induced liver damage in a mouse model of acute severe infection. JHEP Rep 2020;2:100098. [PMID: 32382723 DOI: 10.1016/j.jhepr.2020.100098] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
4 Hernàndez-Èvole H, Briz-Redón Á, Berenguer M. Changing delta hepatitis patient profile: A single center experience in Valencia region, Spain. World J Hepatol 2020; 12(6): 277-287 [PMID: 32742570 DOI: 10.4254/wjh.v12.i6.277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Wangensteen KJ, Chang KM. Multiple Roles for Hepatitis B and C Viruses and the Host in the Development of Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:27-37. [PMID: 32737895 DOI: 10.1002/hep.31481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Zhang Z, Urban S. New insights into HDV persistence: The role of interferon response and implications for upcoming novel therapies. Journal of Hepatology 2021;74:686-99. [DOI: 10.1016/j.jhep.2020.11.032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
7 Kushner T, Da BL, Chan A, Dieterich D, Sigel K, Saberi B. Liver Transplantation for Hepatitis D Virus in the United States: A UNOS Study on Outcomes in the MELD Era. Transplant Direct 2022;8:e1253. [PMID: 34957333 DOI: 10.1097/TXD.0000000000001253] [Reference Citation Analysis]
8 Tham CYL, Kah J, Tan AT, Volz T, Chia A, Giersch K, Ladiges Y, Loglio A, Borghi M, Sureau C, Lampertico P, Lütgehetmann M, Dandri M, Bertoletti A. Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. Cell Rep Med 2020;1:100060. [PMID: 33205065 DOI: 10.1016/j.xcrm.2020.100060] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
9 Giersch K, Hermanussen L, Volz T, Volmari A, Allweiss L, Sureau C, Casey J, Huang J, Fischer N, Lütgehetmann M, Dandri M. Strong Replication Interference Between Hepatitis Delta Viruses in Human Liver Chimeric Mice. Front Microbiol 2021;12:671466. [PMID: 34305837 DOI: 10.3389/fmicb.2021.671466] [Reference Citation Analysis]
10 Maestro S, Gómez-Echarte N, Camps G, Usai C, Suárez L, Vales Á, Olagüe C, Aldabe R, González-Aseguinolaza G. AAV-HDV: An Attractive Platform for the In Vivo Study of HDV Biology and the Mechanism of Disease Pathogenesis. Viruses 2021;13:788. [PMID: 33925087 DOI: 10.3390/v13050788] [Reference Citation Analysis]
11 Shekhtman L, Cotler SJ, Hershkovich L, Uprichard SL, Bazinet M, Pantea V, Cebotarescu V, Cojuhari L, Jimbei P, Krawczyk A, Dittmer U, Vaillant A, Dahari H. Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg. Sci Rep 2020;10:7837. [PMID: 32398799 DOI: 10.1038/s41598-020-64122-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
12 Loureiro D, Castelnau C, Tout I, Boyer N, Narguet S, Menasria Benazzouz S, Louis Z, Pons-Kerjean N, Giuly N, Marcellin P, Mansouri A, Asselah T. New therapies for hepatitis delta virus infection. Liver Int 2021;41 Suppl 1:30-7. [PMID: 34155804 DOI: 10.1111/liv.14838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kefalakes H, Rehermann B. Inflammation drives an altered phenotype of mucosal-associated invariant T cells in chronic hepatitis D virus infection. J Hepatol 2019;71:237-9. [PMID: 31221499 DOI: 10.1016/j.jhep.2019.05.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
14 Bertoletti A, Tan AT. HBV as a target for CAR or TCR-T cell therapy. Curr Opin Immunol 2020;66:35-41. [PMID: 32361634 DOI: 10.1016/j.coi.2020.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
15 Schiller JT, Lowy DR. An Introduction to Virus Infections and Human Cancer. Recent Results Cancer Res 2021;217:1-11. [PMID: 33200359 DOI: 10.1007/978-3-030-57362-1_1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
16 Elsaid MI, Li Y, John T, Narayanan N, Catalano C, Rustgi VK. Economic and Health Care Burdens of Hepatitis Delta: A Study of Commercially Insured Adults in the United States. Hepatology 2020;72:399-411. [PMID: 31804707 DOI: 10.1002/hep.31055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Jackson K, Tekoaua R, Holgate T, Edwards R, Yuen L, Lee A, Nicholson S, Littlejohn M, Locarnini S, Tuneti K. Hepatitis B and D in the Pacific Islands of Kiribati. J Clin Virol 2020;129:104527. [PMID: 32645613 DOI: 10.1016/j.jcv.2020.104527] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
18 Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, Hutin Y, Geretti AM. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73:523-532. [PMID: 32335166 DOI: 10.1016/j.jhep.2020.04.008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 55] [Article Influence: 27.5] [Reference Citation Analysis]
19 Nagra N, Kozarek RA, Burman BE. Therapeutic Advances in Viral Hepatitis A–E. Adv Ther. [DOI: 10.1007/s12325-022-02070-z] [Reference Citation Analysis]
20 Zhang Z, Urban S. Interplay between Hepatitis D Virus and the Interferon Response. Viruses 2020;12:E1334. [PMID: 33233762 DOI: 10.3390/v12111334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Daw MA, Daw AM, Sifennasr NEM, Draha A, Daw A, Daw A, Ahmed M, Mokhtar E, El-Bouzedi A, Daw I, Adam S, Warrag S. The epidemiological characterization and geographic distribution of hepatitis D virus infection in Libya. Pan Afr Med J 2020;35:120. [PMID: 32637018 DOI: 10.11604/pamj.2020.35.120.20055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Rizzetto M, Stroffolini T. Forty-Five Years after the Discovery of the Hepatitis D Virus: Where Do We Stand? Viruses 2021;13:555. [PMID: 33810224 DOI: 10.3390/v13040555] [Reference Citation Analysis]
23 Abeywickrama-Samarakoon N, Cortay JC, Sureau C, Müller S, Alfaiate D, Guerrieri F, Chaikuad A, Schröder M, Merle P, Levrero M, Dény P. Hepatitis Delta Virus histone mimicry drives the recruitment of chromatin remodelers for viral RNA replication. Nat Commun 2020;11:419. [PMID: 31964889 DOI: 10.1038/s41467-020-14299-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Cullaro G, Sharma R, Trebicka J, Cárdenas A, Verna EC. Precipitants of Acute-on-Chronic Liver Failure: An Opportunity for Preventative Measures to Improve Outcomes. Liver Transpl 2020;26:283-93. [PMID: 31714011 DOI: 10.1002/lt.25678] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
25 Da BL, Surana P, Takyar V, Kleiner DE, Heller T, Koh C. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat 2020;27:428-36. [PMID: 31742822 DOI: 10.1111/jvh.13235] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Stelzl E, Ciesek S, Cornberg M, Maasoumy B, Heim A, Chudy M, Olivero A, Miklau FN, Nickel A, Reinhardt A, Dietzsch M, Kessler HH. Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: A European multicenter study. J Clin Virol 2021;142:104932. [PMID: 34333392 DOI: 10.1016/j.jcv.2021.104932] [Reference Citation Analysis]
27 Chen LY, Pang XY, Goyal H, Yang RX, Xu HG. Hepatitis D: challenges in the estimation of true prevalence and laboratory diagnosis. Gut Pathog 2021;13:66. [PMID: 34717740 DOI: 10.1186/s13099-021-00462-0] [Reference Citation Analysis]
28 Puigvehí M, Moctezuma-Velázquez C, Villanueva A, Llovet JM. The oncogenic role of hepatitis delta virus in hepatocellular carcinoma. JHEP Rep 2019;1:120-30. [PMID: 32039360 DOI: 10.1016/j.jhepr.2019.05.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
29 Papatheodoridi M, Papatheodoridis GV. Current status of hepatitis delta. Curr Opin Pharmacol 2021;58:62-7. [PMID: 33895531 DOI: 10.1016/j.coph.2021.03.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Giersch K, Dandri M. In Vivo Models of HDV Infection: Is Humanizing NTCP Enough? Viruses 2021;13:588. [PMID: 33807170 DOI: 10.3390/v13040588] [Reference Citation Analysis]
31 Yurdaydin C, Keskin O, Yurdcu E, Çalişkan A, Önem S, Karakaya F, Kalkan Ç, Karatayli E, Karatayli S, Choong I, Apelian D, Koh C, Heller T, Idilman R, Bozdayi AM, Glenn JS. A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology 2021. [PMID: 34860418 DOI: 10.1002/hep.32259] [Reference Citation Analysis]
32 Vlachogiannakos J, Papatheodoridis GV. New epidemiology of hepatitis delta. Liver Int 2020;40 Suppl 1:48-53. [PMID: 32077599 DOI: 10.1111/liv.14357] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
33 Verrier ER, Salvetti A, Pons C, Michelet M, Rivoire M, Baumert TF, Durantel D, Lucifora J. Loss of hepatitis D virus infectivity upon farnesyl transferase inhibitor treatment associates with increasing RNA editing rates revealed by a new RT-ddPCR method. Antiviral Research 2022. [DOI: 10.1016/j.antiviral.2022.105250] [Reference Citation Analysis]
34 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol 2021;12:671640. [PMID: 34025430 DOI: 10.3389/fphar.2021.671640] [Reference Citation Analysis]
35 Altstetter SM, Quitt O, Pinci F, Hornung V, Lucko AM, Wisskirchen K, Jung S, Protzer U. Hepatitis-D Virus Infection Is Not Impaired by Innate Immunity but Increases Cytotoxic T-Cell Activity. Cells 2021;10:3253. [PMID: 34831475 DOI: 10.3390/cells10113253] [Reference Citation Analysis]